Los Angeles Capital Management LLC Sells 2,600 Shares of Phibro Animal Health Co. (NASDAQ:PAHC)

Los Angeles Capital Management LLC decreased its stake in shares of Phibro Animal Health Co. (NASDAQ:PAHC) by 9.9% in the third quarter, HoldingsChannel reports. The institutional investor owned 23,539 shares of the company’s stock after selling 2,600 shares during the period. Los Angeles Capital Management LLC’s holdings in Phibro Animal Health were worth $530,000 at the end of the most recent quarter.

Several other large investors also recently added to or reduced their stakes in PAHC. Sofinnova Investments Inc. purchased a new stake in shares of Phibro Animal Health in the second quarter valued at approximately $3,975,000. American Century Companies Inc. lifted its holdings in shares of Phibro Animal Health by 119.6% in the 2nd quarter. American Century Companies Inc. now owns 347,191 shares of the company’s stock worth $5,822,000 after buying an additional 189,068 shares during the period. Acadian Asset Management LLC grew its position in shares of Phibro Animal Health by 32.8% during the 1st quarter. Acadian Asset Management LLC now owns 675,207 shares of the company’s stock worth $8,726,000 after buying an additional 166,776 shares in the last quarter. Dana Investment Advisors Inc. increased its stake in shares of Phibro Animal Health by 17.2% during the second quarter. Dana Investment Advisors Inc. now owns 513,926 shares of the company’s stock valued at $8,619,000 after buying an additional 75,546 shares during the period. Finally, AXA S.A. bought a new stake in shares of Phibro Animal Health in the second quarter valued at about $906,000. 99.34% of the stock is owned by hedge funds and other institutional investors.

Phibro Animal Health Price Performance

Shares of PAHC opened at $24.46 on Friday. The company has a 50 day moving average of $22.89 and a two-hundred day moving average of $19.74. The company has a quick ratio of 1.69, a current ratio of 3.23 and a debt-to-equity ratio of 1.81. Phibro Animal Health Co. has a twelve month low of $9.49 and a twelve month high of $25.98. The company has a market cap of $990.63 million, a price-to-earnings ratio of 56.89, a price-to-earnings-growth ratio of 0.66 and a beta of 0.51.

Phibro Animal Health (NASDAQ:PAHC) last announced its earnings results on Wednesday, August 28th. The company reported $0.41 earnings per share for the quarter, topping the consensus estimate of $0.34 by $0.07. Phibro Animal Health had a return on equity of 21.59% and a net margin of 1.67%. The firm had revenue of $273.16 million for the quarter, compared to the consensus estimate of $262.44 million. As a group, analysts predict that Phibro Animal Health Co. will post 1.59 earnings per share for the current fiscal year.

Phibro Animal Health Dividend Announcement

The business also recently disclosed a quarterly dividend, which will be paid on Wednesday, December 18th. Investors of record on Wednesday, November 27th will be given a $0.12 dividend. This represents a $0.48 annualized dividend and a dividend yield of 1.96%. The ex-dividend date of this dividend is Wednesday, November 27th. Phibro Animal Health’s payout ratio is currently 111.63%.

Insider Buying and Selling

In other news, Director E Thomas Corcoran purchased 5,000 shares of the stock in a transaction on Wednesday, September 4th. The stock was bought at an average price of $20.02 per share, with a total value of $100,100.00. Following the transaction, the director now owns 25,000 shares in the company, valued at $500,500. The trade was a 25.00 % increase in their position. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this hyperlink. 50.07% of the stock is owned by company insiders.

Analyst Ratings Changes

Several research firms have recently commented on PAHC. Barclays boosted their price target on shares of Phibro Animal Health from $13.00 to $20.00 and gave the company an “underweight” rating in a report on Tuesday, November 12th. StockNews.com upgraded Phibro Animal Health from a “buy” rating to a “strong-buy” rating in a report on Tuesday, November 12th. Bank of America increased their target price on Phibro Animal Health from $13.00 to $15.00 and gave the company an “underperform” rating in a research report on Friday, August 30th. Finally, JPMorgan Chase & Co. began coverage on Phibro Animal Health in a research report on Tuesday, September 10th. They issued a “neutral” rating and a $22.00 price target for the company. Three research analysts have rated the stock with a sell rating, one has assigned a hold rating and one has issued a strong buy rating to the stock. According to data from MarketBeat, Phibro Animal Health currently has a consensus rating of “Hold” and an average price target of $16.50.

About Phibro Animal Health

Phibro Animal Health Corporation operates as an animal health and mineral nutrition company in the United States, Israel, Brazil, Ireland, and internationally. It operates through three segments: Animal Health, Mineral Nutrition, and Performance Products. The company develops, manufactures, and markets various products for food and companion animals including poultry, swine, beef and dairy cattle, aquaculture, and dogs.